$VRDN
Viridian Therapeutics, Inc.\DE

2020 Q2 Form 10-Q Financial Statement

#000159075020000082 Filed on August 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $168.0K $2.514M
YoY Change -93.32% 15.22%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.710M $2.860M
YoY Change -5.24% 7.12%
% of Gross Profit
Research & Development $3.836M $8.599M
YoY Change -55.39% 2.67%
% of Gross Profit
Depreciation & Amortization $64.00K $100.0K
YoY Change -36.0% 0.0%
% of Gross Profit
Operating Expenses $6.542M $11.46M
YoY Change -42.89% 3.74%
Operating Profit -$6.374M -$8.942M
YoY Change -28.72% 0.91%
Interest Expense -$60.00K $50.00K
YoY Change -220.0% -66.67%
% of Operating Profit
Other Income/Expense, Net $33.00K $275.0K
YoY Change -88.0% -23.82%
Pretax Income -$6.440M -$8.900M
YoY Change -27.64% 2.18%
Income Tax
% Of Pretax Income
Net Earnings -$6.435M -$8.896M
YoY Change -27.66% 2.09%
Net Earnings / Revenue -3830.36% -353.86%
Basic Earnings Per Share -$1.82
Diluted Earnings Per Share -$1.82 -$4.300M
COMMON SHARES
Basic Shares Outstanding 3.538M shares 30.93M shares
Diluted Shares Outstanding 3.538M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.60M $43.90M
YoY Change -30.3% -42.46%
Cash & Equivalents $30.58M $24.01M
Short-Term Investments $0.00 $19.90M
Other Short-Term Assets $1.700M $3.800M
YoY Change -55.26% 0.0%
Inventory
Prepaid Expenses
Receivables $248.0K $325.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $32.52M $48.08M
YoY Change -32.36% -40.8%
LONG-TERM ASSETS
Property, Plant & Equipment $379.0K $652.0K
YoY Change -41.87% 6.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.000K $50.00K
YoY Change -98.0% 0.0%
Total Long-Term Assets $964.0K $702.0K
YoY Change 37.32% 5.72%
TOTAL ASSETS
Total Short-Term Assets $32.52M $48.08M
Total Long-Term Assets $964.0K $702.0K
Total Assets $33.49M $48.78M
YoY Change -31.36% -40.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $286.0K $1.232M
YoY Change -76.79% 167.25%
Accrued Expenses $3.020M $3.946M
YoY Change -23.47% 11.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.400M $4.000M
YoY Change -15.0% 1233.33%
Total Short-Term Liabilities $6.723M $9.148M
YoY Change -26.51% 113.54%
LONG-TERM LIABILITIES
Long-Term Debt $5.400M $6.200M
YoY Change -12.9% -36.73%
Other Long-Term Liabilities $211.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $211.0K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.723M $9.148M
Total Long-Term Liabilities $211.0K $0.00
Total Liabilities $12.31M $15.35M
YoY Change -19.75% 7.94%
SHAREHOLDERS EQUITY
Retained Earnings -$182.7M -$146.8M
YoY Change 24.44% 37.26%
Common Stock $531.0K $310.0K
YoY Change 71.29% 1.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.17M $33.44M
YoY Change
Total Liabilities & Shareholders Equity $33.49M $48.78M
YoY Change -31.36% -40.43%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$6.435M -$8.896M
YoY Change -27.66% 2.09%
Depreciation, Depletion And Amortization $64.00K $100.0K
YoY Change -36.0% 0.0%
Cash From Operating Activities -$6.790M -$7.170M
YoY Change -5.3% 58.98%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$30.00K
YoY Change -100.0% -66.67%
Acquisitions
YoY Change
Other Investing Activities $0.00 $13.05M
YoY Change -100.0% -139.79%
Cash From Investing Activities $0.00 $13.03M
YoY Change -100.0% -139.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.260M -40.00K
YoY Change -3250.0% -101.48%
NET CHANGE
Cash From Operating Activities -6.790M -7.170M
Cash From Investing Activities 0.000 13.03M
Cash From Financing Activities 1.260M -40.00K
Net Change In Cash -5.530M 5.820M
YoY Change -195.02% -116.78%
FREE CASH FLOW
Cash From Operating Activities -$6.790M -$7.170M
Capital Expenditures $0.00 -$30.00K
Free Cash Flow -$6.790M -$7.140M
YoY Change -4.9% 61.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001590750
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201602Member
CY2020Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36483
dei Entity Registrant Name
EntityRegistrantName
MIRAGEN THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1187261
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
dei Entity Address Address Line1
EntityAddressAddressLine1
6200 Lookout Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Boulder
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80301
dei City Area Code
CityAreaCode
720
dei Local Phone Number
LocalPhoneNumber
643-5200
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
MGEN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56610154 shares
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30582000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24846000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2786000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
32521000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
29739000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
379000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2020Q2 us-gaap Assets
Assets
33485000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
1999000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
248000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
108000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1691000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
523000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
584000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1000 USD
CY2019Q4 us-gaap Assets
Assets
30262000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
286000 USD
CY2020Q2 us-gaap Notes Payable Current
NotesPayableCurrent
3417000 USD
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3976000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1096000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3020000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5108000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6723000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10180000 USD
CY2020Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
5380000 USD
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
4328000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
211000 USD
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2020Q2 us-gaap Liabilities
Liabilities
12314000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
14508000 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53077348 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53077348 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34861876 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34861876 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
531000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
349000 USD
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
203291000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
183574000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-182651000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168169000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
21171000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15754000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33485000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8599000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5429000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30262000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
168000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2514000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
996000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2886000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3836000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9939000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17350000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2706000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2857000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6214000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
6542000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
11456000 USD
us-gaap Operating Expenses
OperatingExpenses
15368000 USD
us-gaap Operating Expenses
OperatingExpenses
23564000 USD
CY2019Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
229000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6374000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8942000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-14372000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-20678000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
33000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
275000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
128000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
614000 USD
CY2020Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
94000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
235000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
461000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6435000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-8896000 USD
us-gaap Net Income Loss
NetIncomeLoss
-14479000 USD
us-gaap Net Income Loss
NetIncomeLoss
-20525000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
0 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20525000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
15000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20511000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
9000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
14000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6435000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8887000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14479000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6435000 USD
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8896000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14479000 USD
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53077348 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30983918 shares
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6435000 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49276843 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30935272 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15754000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
13000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
16000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
664000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8044000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
27000000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
623000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
21171000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
51344000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
84000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1018000 USD
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
5000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-11629000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
40956000 USD
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
278000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-8896000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
33437000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
944000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1075000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
9000 USD
us-gaap Net Income Loss
NetIncomeLoss
-14479000 USD
us-gaap Net Income Loss
NetIncomeLoss
-20525000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1287000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2093000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
281000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
132000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
144000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-131000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
139000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
140000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
301000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-762000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-810000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
661000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2412000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
28000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15248000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18983000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
39000000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
28726000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
69000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2001000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10205000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19754000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
426000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1193000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
13000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1726000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1333000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
333000 USD
us-gaap Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
16000 USD
us-gaap Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
84000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18983000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
179000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5736000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8599000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24846000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32606000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30582000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24007000 USD
us-gaap Interest Paid Net
InterestPaidNet
145000 USD
us-gaap Interest Paid Net
InterestPaidNet
277000 USD
mgen Amortization Of Stock Issuance Costs
AmortizationOfStockIssuanceCosts
30000 USD
mgen Amortization Of Stock Issuance Costs
AmortizationOfStockIssuanceCosts
1000 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
19000 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
14000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-182700000 USD
CY2020Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
30600000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-182700000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div>
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2000000.0 USD
CY2020Q2 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2019Q4 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2000000.0 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</span></div>
CY2020Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2019Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2020Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2020Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 USD
CY2019Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
9000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
14000 USD
CY2019Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2019Q2 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2020Q2 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
400000 USD
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
400000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
400000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
379000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
523000 USD
us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
44 position
us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.50
CY2020Q2 us-gaap Restructuring And Related Cost Cost Incurred To Date1
RestructuringAndRelatedCostCostIncurredToDate1
2300000 USD
CY2020Q2 us-gaap Restructuring And Related Cost Expected Cost Remaining1
RestructuringAndRelatedCostExpectedCostRemaining1
100000 USD
CY2020Q2 us-gaap Restructuring Charges
RestructuringCharges
100000 USD
us-gaap Restructuring Charges
RestructuringCharges
200000 USD
CY2019Q2 us-gaap Restructuring Charges
RestructuringCharges
0 USD
us-gaap Restructuring Charges
RestructuringCharges
0 USD
CY2019Q4 us-gaap Restructuring Reserve
RestructuringReserve
1515000 USD
us-gaap Restructuring Charges
RestructuringCharges
208000 USD
us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
39000 USD
us-gaap Payments For Restructuring
PaymentsForRestructuring
1385000 USD
CY2020Q2 us-gaap Restructuring Reserve
RestructuringReserve
377000 USD
CY2019Q4 mgen Contract With Customer Asset Incurred But Not Yet Billed
ContractWithCustomerAssetIncurredButNotYetBilled
300000 USD
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3814000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3871000 USD
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3435000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3348000 USD
CY2019Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000 USD
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000 USD
CY2020Q2 mgen Accrued Outsourcing Clinicaland Preclinical Studies
AccruedOutsourcingClinicalandPreclinicalStudies
959000 USD
CY2019Q4 mgen Accrued Outsourcing Clinicaland Preclinical Studies
AccruedOutsourcingClinicalandPreclinicalStudies
2259000 USD
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
686000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
508000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
397000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
0 USD
CY2020Q2 us-gaap Restructuring Reserve
RestructuringReserve
377000 USD
CY2019Q4 us-gaap Restructuring Reserve
RestructuringReserve
1515000 USD
CY2020Q2 mgen Accrued Legal Fees Current
AccruedLegalFeesCurrent
311000 USD
CY2019Q4 mgen Accrued Legal Fees Current
AccruedLegalFeesCurrent
284000 USD
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
105000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
254000 USD
CY2020Q2 mgen Accrued Liabilityof Warrantson Temporary Equity
AccruedLiabilityofWarrantsonTemporaryEquity
100000 USD
CY2019Q4 mgen Accrued Liabilityof Warrantson Temporary Equity
AccruedLiabilityofWarrantsonTemporaryEquity
100000 USD
CY2020Q2 us-gaap Accrued Rent Current
AccruedRentCurrent
0 USD
CY2019Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
66000 USD
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
85000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
122000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3020000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5108000 USD
mgen Lessee Operating Lease Number Of Renewal Terms
LesseeOperatingLeaseNumberOfRenewalTerms
2 renewal_term
CY2020Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.06
CY2020Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
400000 USD
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
400000 USD
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12M
CY2020Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
100000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
200000 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
100000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
200000 USD
CY2020Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P1Y6M
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
600000 USD
CY2020Q2 mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
100000 USD
CY2019Q2 mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
100000 USD
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q2 mgen Common Stock Voteper Share
CommonStockVoteperShare
1 vote
CY2020Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7535815 shares
mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
200000 USD
mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
200000 USD
CY2020Q2 mgen Capital Stock Shares Authorized
CapitalStockSharesAuthorized
105000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
2557544 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
46522 shares
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.13
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
46522 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
17.93
mgen Classof Warrantor Right Grantsin Period
ClassofWarrantorRightGrantsinPeriod
7500000 shares
mgen Classof Warrantor Right Exercise Priceof Warrantsor Rights Exercised During Period
ClassofWarrantorRightExercisePriceofWarrantsorRightsExercisedDuringPeriod
1.10
mgen Class Of Warrant Or Right Expired In Period
ClassOfWarrantOrRightExpiredInPeriod
10707 shares
mgen Classof Warrantor Right Expired In Period Weighted Average Grant Date Fair Value
ClassofWarrantorRightExpiredInPeriodWeightedAverageGrantDateFairValue
52500
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7535815 shares
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.13
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
4182404 shares
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2017Q1 mgen Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Authorized Percent Of Common Stock Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedPercentOfCommonStockOutstanding
0.04
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
1394475 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
3530773 shares
CY2020Q2 mgen Sharebased Compensation Arrangementby Sharebased Payment Award Equity Awards Outstanding
SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding
4095970 shares
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1541083 shares
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1287000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2093000 USD
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3900000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M9D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12695000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4541000 shares

Files In Submission

Name View Source Status
0001590750-20-000082-index-headers.html Edgar Link pending
0001590750-20-000082-index.html Edgar Link pending
0001590750-20-000082.txt Edgar Link pending
0001590750-20-000082-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mgen-20200630.htm Edgar Link pending
mgen-20200630.xsd Edgar Link pending
mgen-20200630_cal.xml Edgar Link unprocessable
mgen-20200630_def.xml Edgar Link unprocessable
mgen-20200630_htm.xml Edgar Link completed
mgen-20200630_lab.xml Edgar Link unprocessable
mgen-20200630_pre.xml Edgar Link unprocessable
mgen-q22020xex311.htm Edgar Link pending
mgen-q22020xex312.htm Edgar Link pending
mgen-q22020xex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending